Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Sammy Saab, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven J. Knox, Phil Pang, Mani Subramanian, Kris Kowdley, Nezam H. Afdhal

Research output: Contribution to journalArticle

Abstract

Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of

Original languageEnglish
JournalHepatology
DOIs
Publication statusAccepted/In press - 2016

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older'. Together they form a unique fingerprint.

  • Cite this

    Saab, S., Park, S. H., Mizokami, M., Omata, M., Mangia, A., Eggleton, E., Zhu, Y., Knox, S. J., Pang, P., Subramanian, M., Kowdley, K., & Afdhal, N. H. (Accepted/In press). Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. https://doi.org/10.1002/hep.28425